ArticleCancer management and research2021
Solid-Pseudopapillary Neoplasm of the Pancreas: A 63-Case Analysis of Clinicopathologic and Immunohistochemical Features and Risk Factors of Malignancy.
Article in Cancer management and research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 31 citations in OpenAlex.
- Extremely large solid pseudopapillary neoplasm of the pancreas.Clinical journal of gastroenterology · 2026Article
- A Preliminary Study on Contrast Enhanced Ultrasound Characteristics of Solid Pseudopapillary Neoplasms and Pancreatoblastoma in Children.Diagnostics (Basel, Switzerland) · 2026Article
- Solid Pseudopapillary Neoplasm of the Pancreas Showing Spontaneous Regression Followed by Regrowth: A Case Report.Surgical case reports · 2026Article
- Massive calcified solid pseudopapillary neoplasm of the pancreatic head.Oncoscience · 2026Article
- Review
- Emerging pathological diagnostic strategies for solid pseudopapillary neoplasm of the pancreas: insights from omics and innovative techniques.The journal of pathology. Clinical research · 2025Review
- Whole-genome analysis of an aggressive metastatic pancreatic solid pseudopapillary neoplasm.NPJ precision oncology · 2025Article
- Diagnostic utility of LEF1 and β-catenin in WNT pathway tumors with CTNNB1 mutation.World journal of surgical oncology · 2025Article
- Solid pseudopapillary neoplasm (SPN) of the pancreas: current understanding on its malignant potential and management.Discover oncology · 2024Review
- Unraveling the enigma: A comprehensive review of solid pseudopapillary tumor of the pancreas.World journal of gastrointestinal oncology · 2024Review
- Solid pseudopapillary neoplasm of the pancreas with hepatic metastases: problems and strategies.Frontiers in oncology · 2024Review
- Impact of parenchyma-preserving surgical methods on treating patients with solid pseudopapillary neoplasms: A retrospective study with a large sample size.World journal of gastrointestinal surgery · 2022Article
- Current highlights on solid pseudopapillary neoplasm of the pancreas.World journal of hepatology · 2022Article
- The Sex Features of Patients With Solid Pseudopapillary Neoplasms of the Pancreas: A Retrospective Study.Frontiers in oncology · 2022Article
- Case report: A case report and literature review of extrapancreatic solid pseudopapillary neoplasm.Frontiers in surgery · 2022Article
- Solid pseudopapillary neoplasm of the pancreas.World journal of hepatology · 2021Review
- Pediatric Solid Pseudopapillary Neoplasm of the Pancreas.Journal of Indian Association of Pediatric SurgeonsArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeSolid-pseudopapillary neoplasm (SPN) of the pancreas, a rare tumor, has low malignant potential. However, some patients develop metastasis and recurrence after resection, with aggressive biological behaviors. This study aimed to explore the features and risk factors associated with the aggressive biological behaviors of SPNs. PATIENTS AND
methodsWe retrospectively analyzed the clinicopathological and long-term follow-up data of 63 patients diagnosed with SPN at the First Affiliated Hospital of Bengbu Medical College between January 2007 and February 2019.
resultsSixty-three patients presented atypical clinical symptoms. The median tumor size was 7.0 cm (range, 2.4-17 cm), and imaging features were solid and cystic or solid tumors with uneven density. Frequent and diffuse nuclear LEF1 protein expression (94.2%) was observed with LEF1 having a higher sensitivity and specificity. Overall survival significantly correlated with tumor size, Ki-67 index, and lymph node metastasis (
conclusionSPN is a rare low-grade malignancy with a specific pseudopapillary structure. LEF1 is an effective biomarker of SPNs. Although SPNs generally display indolent biological behavior, a large tumor size, high proliferation index, and lymph node metastasis may be risk factors for the aggressive behavior and poor prognosis of SPN.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.